Zacks: Analysts Expect Heron Therapeutics Inc (HRTX) to Announce -$0.47 EPS

Analysts expect Heron Therapeutics Inc (NASDAQ:HRTX) to report ($0.47) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Heron Therapeutics’ earnings, with estimates ranging from ($0.60) to ($0.29). Heron Therapeutics reported earnings per share of ($0.77) during the same quarter last year, which suggests a positive year over year growth rate of 39%. The firm is expected to issue its next quarterly earnings report on Monday, November 5th.

According to Zacks, analysts expect that Heron Therapeutics will report full-year earnings of ($2.19) per share for the current financial year, with EPS estimates ranging from ($2.56) to ($1.81). For the next fiscal year, analysts expect that the business will report earnings of ($0.61) per share, with EPS estimates ranging from ($1.48) to $0.45. Zacks’ EPS calculations are an average based on a survey of research analysts that cover Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.68) by $0.14. Heron Therapeutics had a negative net margin of 411.41% and a negative return on equity of 112.35%. The company had revenue of $17.28 million during the quarter, compared to analyst estimates of $12.82 million. During the same quarter last year, the business posted ($0.80) EPS. Heron Therapeutics’s quarterly revenue was up 103.1% compared to the same quarter last year.

A number of research analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating and set a $43.00 price objective for the company in a research note on Wednesday, July 18th. BidaskClub lowered shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, September 22nd. ValuEngine lowered shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, September 4th. Cantor Fitzgerald set a $50.00 price objective on shares of Heron Therapeutics and gave the company a “buy” rating in a research note on Friday, September 21st. Finally, Mizuho reiterated a “buy” rating and issued a $41.00 price objective on shares of Heron Therapeutics in a research note on Friday, June 22nd. One analyst has rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $52.09.

In other Heron Therapeutics news, VP Kimberly Manhard sold 6,000 shares of the firm’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $32.07, for a total value of $192,420.00. Following the completion of the transaction, the vice president now directly owns 6,000 shares of the company’s stock, valued at approximately $192,420. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Kevin C. Tang sold 2,695,000 shares of the firm’s stock in a transaction on Wednesday, September 12th. The shares were sold at an average price of $35.75, for a total transaction of $96,346,250.00. The disclosure for this sale can be found here. 16.20% of the stock is currently owned by insiders.

A number of large investors have recently made changes to their positions in HRTX. Wells Fargo & Company MN boosted its holdings in Heron Therapeutics by 86.6% in the 1st quarter. Wells Fargo & Company MN now owns 60,545 shares of the biotechnology company’s stock valued at $1,670,000 after purchasing an additional 28,095 shares during the period. Northern Trust Corp boosted its holdings in Heron Therapeutics by 15.7% in the 1st quarter. Northern Trust Corp now owns 628,068 shares of the biotechnology company’s stock valued at $17,335,000 after purchasing an additional 85,109 shares during the period. BlackRock Inc. boosted its holdings in Heron Therapeutics by 18.0% in the 1st quarter. BlackRock Inc. now owns 3,512,721 shares of the biotechnology company’s stock valued at $96,952,000 after purchasing an additional 535,285 shares during the period. New York State Common Retirement Fund boosted its holdings in Heron Therapeutics by 21.0% in the 1st quarter. New York State Common Retirement Fund now owns 58,800 shares of the biotechnology company’s stock valued at $1,623,000 after purchasing an additional 10,200 shares during the period. Finally, BNP Paribas Arbitrage SA boosted its holdings in Heron Therapeutics by 18.6% in the 1st quarter. BNP Paribas Arbitrage SA now owns 11,229 shares of the biotechnology company’s stock valued at $310,000 after purchasing an additional 1,761 shares during the period.

Shares of HRTX stock opened at $29.13 on Friday. Heron Therapeutics has a 12-month low of $14.40 and a 12-month high of $42.90. The company has a market cap of $2.28 billion, a PE ratio of 7.98 and a beta of 1.59.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

See Also: Understanding the different types of bonds

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply